. 2019 Apr 16;104(9):4169–4177. doi: 10.1210/jc.2019-00200

Table 2.

Changes in Metabolic Parameters With Metreleptin

	GLD					PLD
	Baseline (N = 73)	6 Mo (N = 51)	12 Mo (N = 39)	24 Mo (N = 38)	P ^a	Baseline (N = 42)	6 Mo (N = 32)	12 Mo (N = 33)	24 Mo (N = 24)	P ^a
Insulin dose (insulin users only), U/d	225 [100,420]	58 [0,150]	0 [0,50]	0 [0,30]	0.002^b	181 [98,280]	120 [50,220]	100 [50,200]	150 [70,232]	0.13
Triglycerides, mg/dL	441 [230,1164]	190 [130,289]	176 [106,332]	171 [87,337]	<0.0001^c	422 [234,910]	318 [219,501]	311 [179,498]	324 [200,481]	0.065
Glucose, mg/dL	188 ± 83	130 ± 52	110 ± 44	116 ± 43	<0.0001^c	173 ± 82	124 ± 32	135 ± 59	137 ± 63	0.001^c
Hemoglobin A1c, %	8.6 ± 2.4	6.4 ± 1.7	6.0 ± 1.3	6.2 ± 1.6	<0.0001^c	8.1 ± 2.1	7.1 ± 1.3	7.5 ± 1.9	7.4 ± 1.7	0.002^c
Urinary glucose excretion, g/24 h	5.1 [0.8,26]	0.3 [0.1,4.9]	0.3 [0.1,2.9]	0.8 [0.2,4.9]	<0.0001^c	4.0 [0.2,14.1]	0.5 [0.1,4.4]	2.4 [0.3,15.7]	2.3 [0.3,9.6]	0.005^d

Results are presented as median [25th,75th percentile] or mean ± SD.

^{^a}

P value for mixed model across all time points.

^{^b}

P < 0.05 for month 12 vs baseline with Bonferroni correction for multiple comparisons.

^{^c}

P < 0.05 for all follow-up time points vs baseline with Bonferroni correction for multiple comparisons.

^{^d}

P < 0.05 for month 6 vs baseline with Bonferroni correction for multiple comparison.